Prospective validation experiment to document the linezolid exposure required to suppress amplification of less susceptible populations. There was a no-treatment control (A), an AUC employing an NHP profile of 250 mg·h/liter (B), and human exposure profiles of 80, 120, 160, and 250 mg·h/liter administered as a daily dose (C to F); to examine the impact of human exposure profile, we generated AUCs of 120 and 250 mg·h/liter as a continuous infusion (G and H).